Less frequent Ocrevus infusions are just as effective in controlling MS, but may help limit the risk of side effects, per a ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

According to the MS Society, certain medications like ocrelizumab (Ocrevus) can slow the progression of the disease in primary progressive multiple sclerosis, and syponimod (Mayzent) can help with ...

Researchers have made more advancements in multiple sclerosis in the last five years than in the previous 70 years. Knowing ...

Multiple sclerosis (MS) in its end stages involves ... In 2017, the Food and Drug Administration (FDA) approved ocrelizumab (Ocrevus) as the first disease-modifying therapy for people with ...

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

Researchers have made more advancements in multiple sclerosis in the last five years ... To manage her disease, she gets an infusion called Ocrevus every six months and exercises regularly.

Cigna Group shares slumped after the health insurer reported cost pressures from surprisingly high catastrophic medical ...

Roche announced FDA approval for OCREVUS ZUNOVOTM (ocrelizumab & hyaluronidase-ocsq) for relapsing and primary progressive multiple sclerosis (MS). This first subcutaneous injection for both forms ...